Tirzepatide was administered at a dose assumed to be below the lowest clinically applicable dose of 5 mg, based on C max [46], and the same dose was used for retatrutide
To the extent that both compounds have been used in clinical settings, the available data indicate vastly different dosage recommendations, frequency of use, and routes of administration: MK-677 is taken as oral capsules, usually once daily, thanks to its relatively long half-life
OCTN2VT, a splice variant of OCTN2, does not transport carnitine because of the retention in the endoplasmic reticulum caused by insertion of 24 amino acids in the first extracellular loop of OCTN2
Creative Commons Attribution-Share Alike 3.0 Unported license.)
A clinically useful claim requires patient-relevant outcomes, appropriate controls and a favourable benefit-to-risk assessment